Compare Lamb Weston Holdings Inc (LW) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lamb Weston Holdings Inc vs Pfizer Inc — how do they compare? Lamb Weston Holdings Inc trades at $49.24 (market cap $6.81B), while Pfizer Inc trades at $27.83 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 23.3× Lamb Weston Holdings Inc's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Lamb Weston Holdings Inc for 66 Days and Pfizer Inc for 158 Days on average.
| LW | PFE | |
|---|---|---|
Market Cap | $6.81B | $158.56B |
Volume | 4,638,686 | 44,138,282 |
Sector | Consumer Staples | Health |
52-Week High | $66.57 | $29.02 |
52-Week Low | $38.48 | $23.67 |
Typical Hold Time | 66 Days | 158 Days |
Enterprise Value | $10.61B | $210.06B |
Dividend Yield | 3.07% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lamb Weston (LW) trades at $48.09, up 0.38% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 14.17% ROE and trades at a P/E of 26.28. Recent news highlights cost savings exceeding $100 million and positive analyst sentiment for upcoming earnings. Support is firm at $48, aligning with the current price, while resistance sits at $49 and $50.
The outlook is cautiously optimistic given earnings momentum and analyst consensus, but risks include margin pressure from rising costs and competitive threats. The consensus price target of $53.71 suggests upside potential, though net income decline from $1.0B in 2023 to $357M in 2025 warrants monitoring operational efficiency.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
